The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer.
The study is planned to be conducted in Sweden at Uppsala University Hospital. The intention is to start patient recruitment as soon as possible following regulatory approval.
The primary aim of the clinical trial is to document safety in patients with breast cancer. Another key aim is to investigate the contrast enhancement in MRI of primary and secondary tumors.
”The SpagoPix project is running according to plan and we have taken another step towards the target to offer a cancer selective and gadolinium free contrast agent for MRI of solid tumors”, says CEO Mats Hansen.